Unlocked Access
FULL SUPPLEMENT: The New Landscape of Field Cancerization: Proven Efficacy Without Severe Skin Reactions
July 2025 | Volume 24 | Issue 7 | Department | 19911s1 | Copyright © July 2025
Actinic keratosis (AK) is a precancerous lesion that occurs with greatest frequency in individuals aged 60 or older and in men. Given the role of chronic UV exposure in engendering these lesions, they...
Read MoreINDIVIDUAL ARTICLE: Tirbanibulin 1% Ointment: Clinical Trial and Real-World Evidence on Efficacy, Tolerability, Safety, and Patient-Reported Outcomes
July 2025 | Volume 24 | Issue 7 | Supplement Individual Articles | 19912s5 | Copyright © July 2025
Actinic keratosis (AK) is a skin lesion that arises due to chronic sun exposure. Treatment of all AKs is recommended due to their risk of progressing to squamous cell carcinomas (SCCs). Many fiel...
Read MoreINDIVIDUAL ARTICLE: Tirbanibulin 1% Ointment: The Mechanism of Action of a Novel Topical Therapy for Actinic Keratosis
July 2025 | Volume 24 | Issue 7 | Supplement Individual Articles | 19913s13 | Copyright © July 2025
Actinic keratosis (AK) is a common, precancerous skin lesion that may progress to squamous cell carcinoma (SCC). Traditional topical therapies for AKs often require long treatment durations. Thes...
Read MoreINDIVIDUAL ARTICLE: An Algorithm Integrating Acneceuticals Into the Management of Acne Vulgaris
June 2025 | Volume 24 | Issue 6 | Supplement Individual Articles | 08423s13 | Copyright © June 2025
Background: Acne vulgaris is a common, chronic cutaneous disorder with numerous efficacious prescription and procedural treatments. Therapy, however, is hampered by medication in...
Read MoreINDIVIDUAL ARTICLE: The Use of Acneceuticals to Improve Acne Care: Introduction of a New Term and Review of the Literature
June 2025 | Volume 24 | Issue 6 | Supplement Individual Articles | 08422s4 | Copyright © June 2025
Background: Acne is a multifactorial inflammatory skin condition that commonly presents to the dermatology clinic. Treatment generallyinvolves the use of pharmaceuti...
Read MoreUtilization of a Heatmapping Python Program to Visualize Improvements of Skin Hydration After Use of a Moisturizing Lotion or Cream
July 2025 | Volume 24 | Issue 7 | Features | 715 | Copyright © July 2025
Dry skin is both extremely common and an important concern for those who suffer from it. In addition to uncomfortable signs and symptoms, dry skin can be associated with pigmentary changes in ind...
Read MoreFULL SUPPLEMENT: Acneceuticals maximized therapeutic outcomes in a real-world setting
June 2025 | Volume 24 | Issue 6 | Department | 08420s1 | Copyright © June 2025
In this issue:
The Use of Acneceuticals to Improve Acne Care: Introduction of a New Term and Review of the Literature
Acne is the most common cutaneous disease worldwi...
Read MoreINDIVIDUAL ARTICLE: Real-World Clinical Case Series Utilizing Acneceuticals as Monotherapy, Adjunctive, or Maintenance Therapy for Acne Vulgaris
June 2025 | Volume 24 | Issue 6 | Supplement Individual Articles | 08421s19 | Copyright © June 2025
Background: Acne vulgaris is a common, multifactorial inflammatory skin disease for which there are many pharmacologic and procedural interventions. Recent publications have stre...
Read MorePractical Algorithm on Topical Treatment of Flaring Atopic Dermatitis (AD) With or Without Secondary Infection
June 2025 | Volume 24 | Issue 6 | Original Article | 621 | Copyright © June 2025
Acute exacerbations or flares are a key characteristic of atopic dermatitis (AD), often associated with sleep deprivation, as well as experiences of stigmatization, social withdrawal, anxiety, an...
Read MoreRapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis
June 2025 | Volume 24 | Issue 6 | Original Article | 600 | Copyright © June 2025
Background: In the ADORING 1 and 2 phase 3 trials, tapinarof cream 1% once daily (QD) demonstrated significant efficacy and was well tolerated in adults and children down to 2 ye...
Read MoreThiamidol: A Breakthrough Innovation in the Treatment of Hyperpigmentation
June 2025 | Volume 24 | Issue 6 | Original Article | 608 | Copyright © June 2025
Cutaneous hyperpigmentation, including melasma, solar lentigines, and post-inflammatory hyperpigmentation (PIH), results in a significant impact on patients’ quality of life. Unfortunately,...
Read MorePDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact
June 2025 | Volume 24 | Issue 6 | Original Article | 631 | Copyright © June 2025
Phosphodiesterase-4 (PDE4) inhibitors are reshaping the treatment landscape for chronic inflammatory skin diseases by offering effective, non-steroidal options for conditions like psoriasis, atop...
Read MoreExploring the Gut Microbiome's Role in Drug-Induced Photosensitivity: A Need for Deeper Investigation
June 2025 | Volume 24 | Issue 6 | Editorials | e40 | Copyright © June 2025
Social Media as a Catalyst for Health Education and Early Diagnosis of Hidradenitis Suppurativa
June 2025 | Volume 24 | Issue 6 | Editorials | e45 | Copyright © June 2025
Exploring the Potential Dermatological Benefits of CGRP Inhibition: A Case Report
June 2025 | Volume 24 | Issue 6 | Case Reports | 636 | Copyright © June 2025
Calcitonin gene-related peptide (CGRP) is a neuropeptide involved in neurogenic inflammation and vasodilation, playing a key role in the pathophysiology of both migraines and inflammatory skin co...
Read MoreConsiderations on Concurrent Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Isotretinoin
June 2025 | Volume 24 | Issue 6 | Editorials | 638 | Copyright © June 2025
Weight Change and Dose Adjustment in Isotretinoin Therapy: A Retrospective Study
June 2025 | Volume 24 | Issue 6 | Features | 639 | Copyright © June 2025
Isotretinoin is used to treat severe nodulocystic acne. Cumulative doses of 120 to 150 mg/kg have been shown to limit adverse events while maximizing efficacy. Also proven safe, doses of 220 mg/k...
Read MoreNeed for Speed: Topical Roflumilast for Rapid Control of Seborrheic Dermatitis Flares
June 2025 | Volume 24 | Issue 6 | Case Reports | 634 | Copyright © June 2025
Seborrheic dermatitis is a common chronic inflammatory skin condition historically treated with topical antifungals and anti-inflammatory agents. While topical corticosteroids are frequently used...
Read MoreFULL SUPPLEMENT: Nordic European Cutaneous Oncodermatology Management (Necom 6): A Practical Algorithm Integrating Skincare for the Prevention and Treatment of Cutaneous Side Effects of Hormonal Cancer Therapy
May 2025 | Volume 24 | Issue 5 | Department | 49630s1 | Copyright © May 2025
INDIVIDUAL ARTICLE: A Practical Algorithm for the Prevention and Treatment of Cutaneous Side Effects of Hormonal Cancer Therapy
May 2025 | Volume 24 | Issue 5 | Supplement Individual Articles | 49631s3 | Copyright © May 2025
Introduction: Hormonal therapies, typically used in the treatment of breast and prostate cancer patients, have been associated with numerous skin toxicities that can impact quality...
Read More
© 2025 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
